Glasberg, Joao; Talans, Aley; Giollo, Thomas Rivelli; Recchimuzzi, Debora Zachello; Bezerra Neto, Joao Evangelista; Lopez, Rossana Veronica Mendonza; Hoff, Paulo Marcelo Gehm 
; Riechelmann, Rachel P
Fonte: Ecancermedicalscience. Unidade: FM
Assuntos: NEUROENDOCRINOLOGIA, CARCINOMA NEUROENDÓCRINO, NEOPLASIAS, METFORMINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GLASBERG, Joao et al. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, v. 16, 2022Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2022.1369. Acesso em: 03 nov. 2025.APA
Glasberg, J., Talans, A., Giollo, T. R., Recchimuzzi, D. Z., Bezerra Neto, J. E., Lopez, R. V. M., et al. (2022). METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. Ecancermedicalscience, 16. doi:10.3332/ecancer.2022.1369NLM
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2025 nov. 03 ] Available from: https://doi.org/10.3332/ecancer.2022.1369Vancouver
Glasberg J, Talans A, Giollo TR, Recchimuzzi DZ, Bezerra Neto JE, Lopez RVM, Hoff PMG, Riechelmann RP. METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours [Internet]. Ecancermedicalscience. 2022 ; 16[citado 2025 nov. 03 ] Available from: https://doi.org/10.3332/ecancer.2022.1369
